Sunday, October 23, 2016
Noon – 2:00 pm
Cellular therapies are reaching new frontiers. The range of cells utilized and methods of collection and manufacture are critical to optimizing function in clinical applications. Regulatory demands also guide how therapies should be developed. This session will address optimizing collection of MNCs, an important source of therapeutic cells, from both adults and children for cancer treatment. In addition, the manufacture of pancreatic cells being pursued as a means to restore physiological beta cell function in patients with diabetes will be presented in the context of regulatory strategies and outcomes. Presentations of the latest information - with attendee participation- should make this luncheon sizzle!
Director: David Stroncek, MD
Moderator: Deborah Sesok-Pizzini, MD, MBA
Faculty: Kelley Capocelli, MD; Andrew Fesnak, MD; Julia Goldstein, MD; Elina Linetesky, PhD
Location: Hyatt Regency - Ballroom V